Intuitive Surgical Announces Record $77.3 Million First Quarter Revenue, Up 86%
First quarter 2006 instrument and accessory revenue increased 81% to $23.3 million from $12.9 million during the first quarter of 2005. Instrument and accessory revenue growth resulted from a larger installed base of da Vinci® Surgical Systems and increased system usage.
Quarter Ended,
--------------------------------
3/31/06 3/31/05 Increase
---------- ---------- ----------
Revenue ($Millions)
-------------------
Systems $ 42.4 $ 21.3 $ 21.1
Instruments/Accessories 23.3 12.9 10.4
Service/Training 11.6 7.4 4.2
---------- ---------- ----------
$ 77.3 $ 41.6 $ 35.7
========== ========== ==========
da Vinci® Surgical System Unit Sales 35 19 16
========== ========== ==========
First quarter 2006 operating income was $21.7 million compared with $8.9 million for the first quarter of 2005. The results for the first quarter of 2006 included $5.1 million of stock compensation expense in accordance with Statement of Financial Accounting Standards "SFAS" number 123R. Excluding this expense, first quarter 2006 operating income was $26.8 million.
As anticipated, during the first quarter of 2006, Intuitive began to report results on a fully taxed basis. The company's first quarter, 2006 effective tax rate was 39.6%, compared with 5.5% reported for the first quarter of 2005. Although the company has moved to fully taxed reporting, only a small portion of 2006 reported tax expense will result in cash outlay due to the anticipated utilization of net operating loss carry forwards.
Reported net income on a generally accepted accounting principles (GAAP) basis, which includes non-cash stock compensation expense, was $14.5 million, or $0.38 per diluted share, compared with $9.1 million, or $0.25 per diluted share, for the first quarter of 2005. Excluding the impact of stock compensation expenses, first quarter 2006 net income was $17.5 million, or $0.46 per share. A complete reconciliation between GAAP results and results excluding stock compensation is provided in the attached tables.
Intuitive ended the first quarter of 2006 with cash, cash equivalents and investments of $221.5 million, up $18.8 million from the previous quarter end. Cash provided by operations for the first quarter of 2006 was $16.1 million, net of $13.5 million utilized during the quarter to fund working capital requirements.
Commenting on the results Lonnie Smith, Chairman and CEO of Intuitive Surgical said, "We are very pleased with our first quarter revenue growth and the positive market response to our da Vinci® S(TM) System. We remain dedicated to taking surgery beyond the limits of the human hand(TM) and believe that our technology has broad and significant implications for the future of healthcare."
The company will report these results at a conference call today at 1:30 pm PDT. The dial-in numbers for the call are 877-909-3508 for participants located in the U.S. and 517-645-6051 for participants located outside the U.S. The passcode is ISRG and the meeting leader is Mr. Lonnie Smith. To access financial information that will be discussed on the call, please visit Intuitive Surgical's website at www.intuitivesurgical.com.
About Intuitive's Products:
The da Vinci® Surgical System consists of a surgeon's viewing and control console having an integrated, high-performance InSite® 3-D vision system, a patient-side cart consisting of three or four robotic arms that position and precisely maneuver endoscopic instruments and an endoscope, and a variety of articulating EndoWrist® Instruments. By integrating computer-enhanced technology with surgeons' technical skills, Intuitive believes that its system enables surgeons to perform better surgery in a manner never before experienced. The da Vinci® Surgical System seamlessly and directly translates the surgeon's natural hand, wrist and finger movements on instrument controls at the surgeon's console outside the patient's body into corresponding micro-movements of the instrument tips positioned inside the patient through small puncture incisions, or ports.
The Aesop® Endoscope Positioner is a voice-activated robotic arm that automates the critical task of endoscope positioning, providing the surgeon with direct control over a smooth, precise and stable view of the internal surgical field.
The Hermes® Control Center is a centralized system designed to voice control a series of networked "smart" medical devices.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including the following: timing and success of product development and market acceptance of developed products; regulatory approvals, clearances and restrictions; guidelines and recommendations in the health care and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which Intuitive Surgical operates; and unanticipated manufacturing disruptions, delays in regulatory approvals of new manufacturing facilities or the inability to meet demand for products. Words such as "estimate," "project," "plan," "intend," "expect," "anticipate," "believe" and similar expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Intuitive®, da Vinci®, da Vinci® S(TM) InSite®, EndoWrist®, Hermes®, and Aesop® are trademarks or registered trademarks of Intuitive Surgical, Inc.
INTUITIVE SURGICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Quarter Ended March 31,
--------------------------
2006 2005
------------ ------------
Revenue:
Products $ 65,668 $ 34,183
Services 11,590 7,431
------------ ------------
Total revenue 77,258 41,614
Cost of revenue:
Products 19,921 11,155
Services 5,656 3,196
------------ ------------
Total cost of revenue 25,577 14,351
------------ ------------
Gross profit 51,681 27,263
Operating costs and expenses:
Selling, general, and administrative 23,810 14,204
Research and development 6,145 4,145
------------ ------------
Total operating costs and expenses 29,955 18,349
------------ ------------
Income from operations 21,726 8,914
Other income, net 2,201 723
------------ ------------
Income before income tax provision 23,927 9,637
Income tax provision 9,469 533
------------ ------------
Net income $ 14,458 $ 9,104
============ ============
Net earnings per share -
Basic $ 0.40 $ 0.26
============ ============
Diluted $ 0.38 $ 0.25
============ ============
Weighted average shares outstanding
used to compute net earnings
per share -
Basic 36,379 34,517
============ ============
Diluted 37,824 37,021
============ ============
INTUITIVE SURGICAL, INC.
UNAUDITED RECONCILIATION OF GAAP TO NON-GAAP CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Quarter Ended March 31, 2006
--------------------------------------
Quarter
Ended
Non-GAAP March 31,
(Pro Forma) Non-GAAP 2005
Reported Entries * (Pro Forma) As Reported
------------ ----------- ------------ ------------
Revenue:
Products $ 65,668 $ - $ 65,668 $ 34,183
Services 11,590 - 11,590 7,431
------------ ----------- ------------ ------------
Total revenue 77,258 - 77,258 41,614
Cost of revenue:
Products 19,921 (471) 19,450 11,155
Services 5,656 (296) 5,360 3,196
------------ ----------- ------------ ------------
Total cost of revenue 25,577 (767) 24,810 14,351
------------ ----------- ------------ ------------
Gross profit 51,681 767 52,448 27,263
Operating costs and
expenses:
Selling, general,
and administrative 23,810 (3,199) 20,611 14,204
Research and
development 6,145 (1,098) 5,047 4,145
------------ ----------- ------------ ------------
Total operating
costs and
expenses 29,955 (4,297) 25,658 18,349
------------ ----------- ------------ ------------
Income from operations 21,726 5,064 26,790 8,914
Other income, net 2,201 - 2,201 723
------------ ----------- ------------ ------------
Income before income
tax provision 23,927 5,064 28,991 9,637
Income tax provision 9,469 2,004 11,473 533
------------ ----------- ------------ ------------
Net income $ 14,458 $ 3,060 $ 17,518 $ 9,104
============ =========== ============ ============
Net earnings per share -
Basic $ 0.40 $ 0.08 $ 0.48 $ 0.26
============ =========== ============ ============
Diluted $ 0.38 $ 0.08 $ 0.46 $ 0.25
============ =========== ============ ============
Weighted average shares
outstanding used to
compute net earnings
per share -
Basic 36,379 36,379 34,517
============ ============ ============
Diluted 37,824 37,824 37,021
============ ============ ============
* Non-GAAP (Pro forma) entries are to eliminate the impact of stock
option expenses.
Note - To supplement our consolidated financial statements presented
in accordance with generally accepted accounting principles (GAAP), we have
presented “Non-GAAP (pro forma)” information, which reflects our results
based on GAAP excluding stock compensation expense under SFAS 123R.
This “Non-GAAP” information is provided to enhance the user's overall
understanding of our current financial performance and our prospects for
the future. Specifically, we believe the “Non-GAAP” results provide useful
information to both management and investors by excluding SFAS 123R
compensation charges that we believe are not indicative of our core
operating results. Further, these “Non-GAAP” results are one of the primary
indicators management uses for assessing our performance, allocating
resources and planning and forecasting future periods. These measures
should be considered in addition to results prepared in accordance with
GAAP, but should not be considered a substitute for, or superior to, GAAP
results.
INTUITIVE SURGICAL, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
3/31/06 12/31/05
------------ ------------
Cash, cash equivalents, and investments $ 221,491 $ 202,739
Accounts receivable, net 56,975 52,849
Inventory, net 20,368 15,170
Property and equipment, net 53,861 52,225
Goodwill 124,638 124,638
Deferred tax assets 32,760 40,758
Other assets 14,410 13,208
------------ ------------
Total Assets $ 524,503 $ 501,587
============ ============
Accounts payable and other accrued liabilities $ 28,015 $ 33,485
Deferred revenue 27,797 25,511
------------ ------------
Total liabilities 55,812 58,996
Stockholders' equity 468,691 442,591
------------ ------------
Total liabilities and stockholders' equity $ 524,503 $ 501,587
============ ============
INTUITIVE SURGICAL, INC.
UNAUDITED SELECTED CONSOLIDATED STATEMENT OF CASH FLOWS DATA
(IN THOUSANDS)
Three months ended
-------------------------
3/31/06 3/31/05
----------- -----------
Net Income $ 14,458 $ 9,104
Depreciation and amortization 2,174 1,667
Deferred income tax 7,999 -
Stock option expense 5,064 -
Changes in operating assets and liabilities (13,490) 1,635
Other, net (89) (58)
----------- -----------
Net cash provided by operating activities $ 16,116 $ 12,348
=========== ===========
----------- -----------
Acquisition of property and equipment ($ 3,204) ($ 1,001)
=========== ===========
----------- -----------
Proceeds from issuance of common stock $ 6,501 $ 6,958
=========== =========== Contacts:Ben Gong
408-523-2175
Sarah Norton
408-523-2161